Prabhu Narayan 4

What Happened
Prabhu Narayan, Chief Financial Officer of Reviva Pharmaceuticals Holdings, Inc. (RVPH), received an option award on March 18, 2026 to acquire rights to 40,925 shares (reported as a derivative award; acquisition price $0). The exercise price will be equal to the company’s closing common stock price on the grant date per the issuer’s 2020 Equity Incentive Plan. This was a grant of options (compensation), not an immediate purchase or sale of shares.

Key Details

• Transaction date: March 18, 2026; Form 4 filed March 20, 2026.
• Award size: options covering 40,925 shares; reported value at grant: $0 (derivative award).
• Vesting: 12,789 shares vest immediately on the grant date; the remaining 28,136 vest in equal monthly installments from April 2026 through December 2028 (see footnote).
• Exercise price: set to the closing price of Reviva common stock on March 18, 2026 (per the 2020 Equity Incentive Plan).
• Shares owned after transaction: not specified in the filing.
• Filing timeliness: filed two days after the grant date (no late filing indicated).

Context
This is a compensation-related option grant (award), a common way companies pay executives; it does not involve an immediate cash outlay or sale. Because the exercise price is tied to the grant-date closing price, the options are essentially at- or near-market at grant; any future value depends on stock performance and vesting. Awards like this are not the same signal as an insider purchase (which can reflect a direct personal investment).